- Home
- LIEN vs AVIR Comparison
LIEN vs AVIR Comparison
Compare LIEN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- AVIR
- Stock Information
- Founded
- LIEN 2021
- AVIR 2012
- Country
- LIEN United States
- AVIR United States
- Employees
- LIEN N/A
- AVIR N/A
- Industry
- LIEN
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LIEN
- AVIR Health Care
- Exchange
- LIEN NYSE
- AVIR Nasdaq
- Market Cap
- LIEN 292.1M
- AVIR 247.5M
- IPO Year
- LIEN 2022
- AVIR 2020
- Fundamental
- Price
- LIEN $11.99
- AVIR $3.42
- Analyst Decision
- LIEN
- AVIR Hold
- Analyst Count
- LIEN 0
- AVIR 1
- Target Price
- LIEN N/A
- AVIR $6.88
- AVG Volume (30 Days)
- LIEN 9.5K
- AVIR 556.5K
- Earning Date
- LIEN 11-07-2024
- AVIR 02-26-2025
- Dividend Yield
- LIEN 8.95%
- AVIR N/A
- EPS Growth
- LIEN N/A
- AVIR N/A
- EPS
- LIEN 0.67
- AVIR N/A
- Revenue
- LIEN $12,681,914.00
- AVIR N/A
- Revenue This Year
- LIEN N/A
- AVIR N/A
- Revenue Next Year
- LIEN N/A
- AVIR N/A
- P/E Ratio
- LIEN $18.27
- AVIR N/A
- Revenue Growth
- LIEN 22.94
- AVIR N/A
- 52 Week Low
- LIEN $7.29
- AVIR $2.75
- 52 Week High
- LIEN $13.38
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- AVIR 62.36
- Support Level
- LIEN N/A
- AVIR $3.19
- Resistance Level
- LIEN N/A
- AVIR $3.32
- Average True Range (ATR)
- LIEN 0.00
- AVIR 0.12
- MACD
- LIEN 0.00
- AVIR 0.04
- Stochastic Oscillator
- LIEN 0.00
- AVIR 94.78
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).